G-CSF prophylactic strategies and neutropenia-related outcomes in patients with breast cancer and non-Hodgkin lymphoma: a real-world observational study

Granulocyte colony-stimulating factor (G-CSF) is recommended for preventing febrile neutropenia (FN) in patients receiving chemotherapy who are at increased risk. However, evidence regarding G-CSF selection and optimal filgrastim prophylaxis duration remains limited. This study aimed to assess the associations between different G-CSF prophylactic strategies and neutropenia-related outcomes among patients with breast cancer or non-Hodgkin lymphoma. A retrospective longitudinal observational study at K Hospital (January–March 2025), included patients receiving chemotherapy regimens with high or intermediate FN risk according to NCCN 2025. Neutropenia was graded using CTCAE v5.0. Associations were evaluated using propensity score overlap-weighted generalized estimating equations (GEE) in post hoc pairwise analyses. A total of 287 patients (1093 chemotherapy cycles) were included. Incidences of any-grade neutropenia, severe neutropenia, and neutropenia-related events were 18.7%, 3.6%, and 2.9%, respectively. In the pooled analysis involving both cancer types (691 cycles), filgrastim administered for 4–5 days was associated with higher odds of any-grade neutropenia than pegfilgrastim (33.8% vs. 4.7%; OR, 12.42; 95% CI, 5.43–28.40). Similar associations were observed in breast cancer-specific analyses for filgrastim administered for 1–3 days (680 cycles; OR, 9.23; 95% CI, 3.95–21.54) and 4–5 days among patients aged ≤65 years (462 cycles; OR, 12.50; 95% CI, 5.15–30.37). Estimates reflected distinct overlap populations, and reliable adjusted comparisons were not possible for non-Hodgkin lymphoma alone. G-CSF prophylactic strategies were associated with differences in documented any-grade neutropenia, but limited treatment overlap, potential residual confounding, and few clinically important events warrant cautious interpretation.

Authors

Institutions

Publication Details

Journal
Tạp chí Nghiên cứu Dược và Thông tin Thuốc
Published
2026-11-17
DOI
https://doi.org/10.59882/1859-364x/481
Primary Topic
Neutropenia and Cancer Infections
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

G-CSF prophylactic strategies and neutropenia-related outcomes in patients with breast cancer and non-Hodgkin lymphoma: a real-world observational study

Nguyễn Thị Hồng Hạnh, Trang Thi Thu Tran, Nga Huyen Do, Nguyễn Thị Liên Hương et al.
Tạp chí Nghiên cứu Dược và Thông tin Thuốc
Neutropenia and Cancer Infections
article

G-CSF prophylactic strategies and neutropenia-related outcomes in patients with breast cancer and non-Hodgkin lymphoma: a real-world observational study

Nguyễn Thị Hồng Hạnh, Trang Thi Thu Tran, Nga Huyen Do, Nguyễn Thị Liên Hương, Ha Viet Le, Tien Dinh Vu, Dang Huynh Hai Bui
article en

Abstract

Granulocyte colony-stimulating factor (G-CSF) is recommended for preventing febrile neutropenia (FN) in patients receiving chemotherapy who are at increased risk. However, evidence regarding G-CSF selection and optimal filgrastim prophylaxis duration remains limited. This study aimed to assess the associations between different G-CSF prophylactic strategies and neutropenia-related outcomes among patients with breast cancer or non-Hodgkin lymphoma. A retrospective longitudinal observational study at K Hospital (January–March 2025), included patients receiving chemotherapy regimens with high or intermediate FN risk according to NCCN 2025. Neutropenia was graded using CTCAE v5.0. Associations were evaluated using propensity score overlap-weighted generalized estimating equations (GEE) in post hoc pairwise analyses. A total of 287 patients (1093 chemotherapy cycles) were included. Incidences of any-grade neutropenia, severe neutropenia, and neutropenia-related events were 18.7%, 3.6%, and 2.9%, respectively. In the pooled analysis involving both cancer types (691 cycles), filgrastim administered for 4–5 days was associated with higher odds of any-grade neutropenia than pegfilgrastim (33.8% vs. 4.7%; OR, 12.42; 95% CI, 5.43–28.40). Similar associations were observed in breast cancer-specific analyses for filgrastim administered for 1–3 days (680 cycles; OR, 9.23; 95% CI, 3.95–21.54) and 4–5 days among patients aged ≤65 years (462 cycles; OR, 12.50; 95% CI, 5.15–30.37). Estimates reflected distinct overlap populations, and reliable adjusted comparisons were not possible for non-Hodgkin lymphoma alone. G-CSF prophylactic strategies were associated with differences in documented any-grade neutropenia, but limited treatment overlap, potential residual confounding, and few clinically important events warrant cautious interpretation.

Tạp chí Nghiên cứu Dược và Thông tin ThuốcVol. 33
Hanoi University of Pharmacy (VN)
Neutropenia and Cancer Infections
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon